8-KEarnings & Results

BIOGEN INC. 8-K Report, Financial Results (Jul 1, 2026)

Filed July 1, 2026For Securities:BIIB

Summary

Biogen Inc. (BIIB) has filed a Form 8-K on July 1, 2026, to provide preliminary updates on its expected financial results for the second and third quarters of 2026. The primary driver of the disclosed impact is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaborations and license agreements. These costs are significant and are expected to impact both GAAP and non-GAAP earnings per diluted share. For the second quarter of 2026, Biogen anticipates an IPR&D expense of approximately $164 million pre-tax, translating to an impact of roughly $0.95 per diluted share. Looking ahead to the third quarter of 2026, the company expects a broader range of IPR&D expenses, estimated between $290 million and $320 million, which could affect earnings per diluted share by approximately $1.75 to $1.95. Investors should note that these are preliminary estimates and are subject to change as financial closing procedures are completed.

Key Highlights

  • 1Biogen expects acquired IPR&D, upfront, and milestone expenses to impact Q2 2026 results.
  • 2Estimated pre-tax charge for Q2 2026 IPR&D is approximately $164 million.
  • 3Q2 2026 IPR&D expense is projected to reduce GAAP and non-GAAP EPS by approximately $0.95.
  • 4Biogen anticipates a higher range of IPR&D expenses for Q3 2026, between $290 million and $320 million.
  • 5The projected Q3 2026 IPR&D expense is expected to impact GAAP and non-GAAP EPS by $1.75 to $1.95.
  • 6These expenses relate to collaborations, license agreements, and potential milestones/transactions.
  • 7The disclosed figures are preliminary estimates and subject to change pending final financial closing procedures.

Frequently Asked Questions

The primary reason for the expected impact on Biogen's earnings is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaboration and license agreements. These costs are associated with potential future milestones and transactions that have not yet closed.

Biogen anticipates that the acquired IPR&D, upfront, and milestone expenses for the second quarter of 2026 will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.95.

For the third quarter of 2026, Biogen expects acquired IPR&D, upfront, and milestone expenses to range from approximately $290 million to $320 million. This is projected to impact GAAP and non-GAAP net income per diluted share by approximately $1.75 to $1.95.

No, the figures provided are preliminary, unaudited estimates. The results for the quarter ended June 30, 2026, have not been finalized and are subject to Biogen's financial statement closing procedures. There is no assurance that the final reported results will not differ from these estimates.